All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rituximab
Therapeutic Area: Oncology Product Name: Halpryza
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
Details:
Halpryza (rituximab injection) is Innovent’s fourth monoclonal antibody drug approved by the NMPA following TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection) and SULINNO® (adalimumab injection).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sintilimab
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: $200.0 million
Deal Type: Collaboration October 07, 2020
Details:
Innovent Biologics announce the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, in connection with global expansion collaboration agreement between the company and Eli Lilly for TYVYT (sintilimab injection).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sintilimab,Bevacizumab
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
The ORIENT-32 trial evaluating TYVYT® in combination with BYVASDA® as a first-line treatment in advanced hepatocellular carcinoma met the predefined primary endpoints of progression-free survival (PFS) and overall survival (OS) in an interim analysis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sintilimab,Pemetrexed Disodium,Platinum
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
The ORIENT-11 primary clinical results were released during the IASLC World Conference on Lung Cancer (WCLC) 2020 Virtual Presidential Symposium as an oral presentation and simultaneously published by the Journal of Thoracic Oncology.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sintilimab,Gemcitabine,Platinum
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
ORIENT-12 is the first randomized, double-blind, Phase 3 clinical trial evaluating TYVYT® or placebo in combination with GEMZAR® and platinum chemotherapy as first-line treatment for advanced or metastatic squamous non-small cell lung cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: Sulinno
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
SULINNO® (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis in China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IBI112
Therapeutic Area: Immunology Product Name: IBI112
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
The study CIBI112A101 is a randomized, double-blind, placebo-controlled, dose-escalation Phase I clinical trial to evaluate the safety and tolerability in addition with PK/PD of IBI112 when administered as a single subcutaneous or intravenous dose in healthy Chinese subjects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tafolecimab
Therapeutic Area: Cardiology/Vascular Diseases Product Name: IBI306
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
Phase 1 and Phase 2 clinical study results of the recombinant fully human monoclonal antibody Tafolecimab (IBI306) were successfully presented in the 2020 European Society of Cardiology (ESC) annual conference.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sintilimab,Pemetrexed Disodium,Platinum
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,025.0 million Upfront Cash: $200.0 million
Deal Type: Licensing Agreement August 18, 2020
Details:
TYVYT is the only PD-1 inhibitor to be included in China's National Reimbursement Drug List (NRDL) and is included in the 2019 Guidelines of Chinese Society of Clinical Oncology for Lymphoid Malignancies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sintilimab,Gemcitabine,Platinum
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application for TYVYT® (sintilimab injection) in combination with Gemzar® (gemcitabine) and platinum as first-line therapy in squamous non-small cell lung cancer (squamous NSCLC).
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
